Friday, the FDA granted emergency use authorization to Invivyd Inc’s (NASDAQ:IVVD) Pemgarda (pemivibart), formerly VYD222, a half-life extended monoclonal antibody (mAb) for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents who have moderate-to-severe immune compromise. “We are proud that roughly one year after initiating the Phase 1 trial of our mAb now known as PEMGARDA, we are expecting to have product available for order imminently, with initial supply already packaged and awaiting final release at our U.S.-based third-party logistics provider,” said Dave Heri…
